R P value
Patient number (n) 0.032 0.862
Age (year) -0.222 0.905
Gender F/M (n) 0.128 0.491
HTN (n, %) 0.081 0.666
DM (n, %) -0.099 0.598
HBV (n, %) 0.314 0.085
HCV (n, %) -0.38 0.839
Smoke (n, %) 0.177 0.341
BMI (kg/m2) 0.016 0.933
HD/PD (n) -0.23 0.213
Pathology diagnosis 0.281 0.125
Drug 0.18 0.332
SBP (mmHg) -0.166 0.371
DBP (mmHg) -0.296 0.106
eGFR (biopsy) (ml/min) -0.238 0.196
eGFR (baseline) (ml/min) -0.307 0.093
eGRF (terminal) (ml/min) -0.78 <0.001*
SCr (biopsy) (mg/dl) 0.232 0.21
SCr (baseline) (mg/dl) 0.342 0.06
SCr (terminal) (mg/dl) 0.784 <0.001*
Hemoglobin (g/dl) 0.029 0.877
HbA1C (%) 0.025 0.898
Low-density lipoprotein (mg/dl) 0.078 0.686
Total cholesterol (mg/dl) -0.079 0.671
Triglyceride (mg/dl) -0.184 0.322
Albumin (mg/dl) -0.427 0.024
Uric acid (mg/dl) 0.091 0.638
Urine dipstick protein(mg/dL) 0.309 0.09
Composite outcome: first event with doubling of SCr or declining eGFR more than 30%
HTN, hypertension; DM, diabetes mellitus; HBV, hepatitis B; HCV, hepatitis C; BMI, body mass index; HD, hemodialysis; PD, peritoneal dialysis; SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration; SCr, serum creatinine; HbA1C, hemoglobin A1c.
*: p<0.05indicates significance
Table 3: Spearman’s correlation association between clinical variables when reaching composite outcome.